Trehalose prevents glyphosate-induced hepatic steatosis in roosters by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation

The role of bioactive compounds in the management of metabolic and alcohol-related liver disease

Metabolic and alcohol-related liver disease (MetALD) is a newly defined category within the spectrum of steatotic liver diseases, designed to capture the interplay between metabolic dysfunction and alcohol consumption more effectively. Bioactive compounds, celebrated for their potent antioxidant, anti-inflammatory, and hepatoprotective properties, have emerged as promising therapeutic agents for the management of MetALD. This review comprehensively examines the underlying mechanisms by which these compounds exert their effects, including the modulation of oxidative stress pathways, the enhancement of lipid metabolism, and the promotion of liver regeneration. Specific bioactive constituents, such as polyphenols, flavonoids, and omega-3 fatty acids, have demonstrated potential in ameliorating hepatic steatosis and fibrosis associated with MetALD. Incorporating these natural compounds into treatment regimens presents a novel strategy for managing MetALD, with significant implications for both lifestyle modifications and pharmacological interventions. Future research should prioritize clinical trials, improvements in bioavailability, and investigations into the synergistic effects of multi-compound formulations to establish effective and sustainable treatment strategies for MetALD.

Oligomeric proanthocyanidins ameliorates osteoclastogenesis through reducing OPG/RANKL ratio in chicken's embryos

Skeletal disorders can seriously threaten the health and the performance of poultry, such as tibial dyschondroplasia (TD) and osteoporosis (OP). Oligomeric proanthocyanidins (OPC) are naturally occurring polyphenolic flavonoid compounds that can be used as potential substances to improve the bone health and the growth performance of poultry. Eighty 7-day-old green-eggshell yellow feather layer chickens were randomly divided into 4 groups: basal diet and basal diet supplementation with 25, 50, and 100 mg/kg OPC. The results have indicated that the growth performance and bone parameters of chickens were significantly improved supplementation with OPC in vivo, including the bone volume (BV), the bone mineral density (BMD) and the activities of antioxidative enzymes, but ratio of osteoprotegerin (OPG)/receptor activator of NF-κB (RANK) ligand (RANKL) was decreased. Furthermore, primary bone marrow mesenchymal stem cells (BMSCs) and bone marrow monocytes/macrophages (BMMs) were successfully isolated from femur and tibia of chickens, and co-cultured to differentiate into osteoclasts in vitro. The osteogenic differentiation derived from BMSCs was promoted treatment with high concentrations of OPC (10, 20, and 40 µmol/L) groups in vitro, but emerging the inhibition of osteoclastogenesis by increasing the ratio of OPG/RANKL. In contrary, the osteogenic differentiation was also promoted treatment with low concentrations of OPC (2.5, 5, and 10 µmol/L) groups, but osteoclastogenesis was enhanced by decreasing the ratio of OPG/RANKL in vitro. In addition, OPG inhibits the differentiation and activity of osteoclasts by increasing the autophagy in vitro. Dietary supplementation of OPC can improve the growth performance of bone and alter the balance of osteoblasts and osteoclasts, thereby improving the bone health of chickens.